Is JANX or TNGX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Tango Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Tango Therapeutics N/A -25.75% -23.36%

Does the media favor JANX or TNGX?

In the previous week, Janux Therapeutics had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 6 mentions for Janux Therapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.29 beat Janux Therapeutics' score of 0.57 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or VKTX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Viking Therapeutics N/A -94.56% -82.75%

Does the media prefer JANX or VKTX?

In the previous week, Viking Therapeutics had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Viking Therapeutics and 6 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.57 beat Viking Therapeutics' score of 0.37 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PBLS or JANX more profitable?

Parabilis Medicines' return on equity of 0.00% beat Janux Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A Janux Therapeutics N/A -11.89% -11.13%

Does the media refer more to PBLS or JANX?

In the previous week, Janux Therapeutics had 3 more articles in the media than Parabilis Medicines. MarketBeat recorded 6 mentions for Janux Therapeutics and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Janux Therapeutics' score of 0.57 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, JANX or VCYT?

Veracyte has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Janux Therapeutics $10M 105.04 -$113.62M -$1.64 N/A Veracyte $517.15M 6.70 $66.35M $1.41 30.57

Does the media prefer JANX or VCYT?

In the previous week, Janux Therapeutics and Janux Therapeutics both had 6 articles in the media. Janux Therapeutics' average media sentiment score of 0.57 beat Veracyte's score of 0.54 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is XENE or JANX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -43.98% -41.72% Janux Therapeutics N/A -11.89% -11.13%

Does the media refer more to XENE or JANX?

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 6 mentions for Janux Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Janux Therapeutics' score of 0.57 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Janux Therapeutics (JANX) Competitors

$17.32 +0.14 (+0.84%)

As of 09:56 AM Eastern

Compare

JANX vs. TNGX, VKTX, PBLS, VCYT, and XENE

Should you buy Janux Therapeutics stock or one of its competitors? Janux Therapeutics's main competitors and comparable companies include Tango Therapeutics (TNGX), Viking Therapeutics (VKTX), Parabilis Medicines (PBLS), Veracyte (VCYT), and Xenon Pharmaceuticals (XENE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Janux Therapeutics compare to Tango Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Janux Therapeutics had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 6 mentions for Janux Therapeutics and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 1.29 beat Janux Therapeutics' score of 0.57 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Janux Therapeutics currently has a consensus target price of $36.46, suggesting a potential upside of 112.23%. Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 95.60%. Given Janux Therapeutics' higher possible upside, equities analysts clearly believe Janux Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Tango Therapeutics has higher revenue and earnings than Janux Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	105.04	-$113.62M	-$1.64	N/A
Tango Therapeutics	$62.38M	60.06	-$101.59M	-$0.85	N/A

Janux Therapeutics' return on equity of -11.89% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Tango Therapeutics	N/A	-25.75%	-23.36%

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Janux Therapeutics beats Tango Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Viking Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Viking Therapeutics had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Viking Therapeutics and 6 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.57 beat Viking Therapeutics' score of 0.37 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Janux Therapeutics has higher revenue and earnings than Viking Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	105.04	-$113.62M	-$1.64	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Janux Therapeutics' return on equity of -11.89% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Viking Therapeutics	N/A	-94.56%	-82.75%

Janux Therapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Janux Therapeutics currently has a consensus target price of $36.46, indicating a potential upside of 112.23%. Viking Therapeutics has a consensus target price of $99.44, indicating a potential upside of 273.15%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Janux Therapeutics beats Viking Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Janux Therapeutics compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Parabilis Medicines' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Janux Therapeutics	N/A	-11.89%	-11.13%

In the previous week, Janux Therapeutics had 3 more articles in the media than Parabilis Medicines. MarketBeat recorded 6 mentions for Janux Therapeutics and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Janux Therapeutics' score of 0.57 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has higher revenue and earnings than Parabilis Medicines. Parabilis Medicines is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	-$145.89M	-$2.13	N/A
Janux Therapeutics	$10M	105.04	-$113.62M	-$1.64	N/A

Parabilis Medicines presently has a consensus price target of $41.67, suggesting a potential upside of 55.18%. Janux Therapeutics has a consensus price target of $36.46, suggesting a potential upside of 112.23%. Given Janux Therapeutics' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Janux Therapeutics beats Parabilis Medicines on 8 of the 12 factors compared between the two stocks.

How does Janux Therapeutics compare to Veracyte?

Janux Therapeutics (NASDAQ:JANX) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Veracyte has a net margin of 20.37% compared to Janux Therapeutics' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Veracyte	20.37%	9.26%	8.61%

In the previous week, Janux Therapeutics and Janux Therapeutics both had 6 articles in the media. Janux Therapeutics' average media sentiment score of 0.57 beat Veracyte's score of 0.54 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics presently has a consensus price target of $36.46, indicating a potential upside of 112.23%. Veracyte has a consensus price target of $55.78, indicating a potential upside of 29.38%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Janux Therapeutics is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Janux Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Veracyte has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	105.04	-$113.62M	-$1.64	N/A
Veracyte	$517.15M	6.70	$66.35M	$1.41	30.57

75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 1.6% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Janux Therapeutics beats Veracyte on 8 of the 15 factors compared between the two stocks.

How does Janux Therapeutics compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Janux Therapeutics (NASDAQ:JANX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Janux Therapeutics' return on equity of -11.89% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Janux Therapeutics	N/A	-11.89%	-11.13%

Xenon Pharmaceuticals currently has a consensus target price of $70.14, suggesting a potential upside of 103.79%. Janux Therapeutics has a consensus target price of $36.46, suggesting a potential upside of 112.23%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market.

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 6 mentions for Janux Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Janux Therapeutics' score of 0.57 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Janux Therapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	443.65	-$345.91M	-$4.74	N/A
Janux Therapeutics	$10M	105.04	-$113.62M	-$1.64	N/A

Summary

Janux Therapeutics beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Janux Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JANX vs. The Competition

Export

Metric	Janux Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.06B	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-10.53	11.31	206.66	19.94
Price / Sales	105.63	1,148.46	562.21	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.09	17.08	10.75	6.03
Net Income	-$113.62M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-3.59%	-4.43%	-2.91%	-2.34%
1 Month Performance	-0.20%	-12.48%	-7.38%	-5.31%
1 Year Performance	-32.86%	7.60%	2.96%	-2.94%

Janux Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JANX Janux Therapeutics	2.5211 of 5 stars	$17.28 +0.6%	$36.46 +111.1%	-34.7%	$1.06B	$10M	N/A	113
TNGX Tango Therapeutics	2.1348 of 5 stars	$23.08 -0.7%	$43.46 +88.3%	+162.3%	$3.92B	$62.38M	N/A	137	Positive News
VKTX Viking Therapeutics	3.3142 of 5 stars	$29.28 -2.2%	$99.67 +240.4%	-21.4%	$3.77B	N/A	N/A	65
PBLS Parabilis Medicines	2.3968 of 5 stars	$29.53 -2.5%	$41.67 +41.1%	N/A	$3.74B	N/A	N/A	145
VCYT Veracyte	4.2631 of 5 stars	$47.67 +4.1%	$55.78 +17.0%	+26.5%	$3.68B	$561.90M	33.81	755

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JANX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Competitors

JANX vs. TNGX, VKTX, PBLS, VCYT, and XENE

How does Janux Therapeutics compare to Tango Therapeutics?

Summary

How does Janux Therapeutics compare to Viking Therapeutics?

Summary

How does Janux Therapeutics compare to Parabilis Medicines?

Summary

How does Janux Therapeutics compare to Veracyte?

Summary

How does Janux Therapeutics compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Competitors

JANX vs. TNGX, VKTX, PBLS, VCYT, and XENE

How does Janux Therapeutics compare to Tango Therapeutics?

Does the media favor JANX or TNGX?

Which has more risk & volatility, JANX or TNGX?

Do analysts prefer JANX or TNGX?

Which has higher earnings & valuation, JANX or TNGX?

Is JANX or TNGX more profitable?

Do institutionals and insiders hold more shares of JANX or TNGX?

Summary

How does Janux Therapeutics compare to Viking Therapeutics?

Do institutionals & insiders believe in JANX or VKTX?

Does the media prefer JANX or VKTX?

Which has higher valuation and earnings, JANX or VKTX?

Is JANX or VKTX more profitable?

Which has more volatility and risk, JANX or VKTX?

Do analysts prefer JANX or VKTX?

Summary

How does Janux Therapeutics compare to Parabilis Medicines?

Do institutionals and insiders hold more shares of PBLS or JANX?

Is PBLS or JANX more profitable?

Does the media refer more to PBLS or JANX?

Which has preferable earnings & valuation, PBLS or JANX?

Do analysts recommend PBLS or JANX?

Summary

How does Janux Therapeutics compare to Veracyte?

Is JANX or VCYT more profitable?

Does the media prefer JANX or VCYT?

Do analysts prefer JANX or VCYT?

Which has more risk & volatility, JANX or VCYT?

Which has preferable valuation and earnings, JANX or VCYT?

Do institutionals & insiders believe in JANX or VCYT?

Summary

How does Janux Therapeutics compare to Xenon Pharmaceuticals?

Is XENE or JANX more profitable?

Do analysts prefer XENE or JANX?

Do institutionals & insiders hold more shares of XENE or JANX?

Which has more volatility and risk, XENE or JANX?

Does the media refer more to XENE or JANX?

Which has stronger earnings & valuation, XENE or JANX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX vs. The Competition

Janux Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools